NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
Clinical Trials
132 trialsNCT06330805 2026-03-09
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT07455903 2026-03-06
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Baptist Health South Florida
Phase 2 Not yet recruiting
NCT07444983 2026-03-03
Rezvilutamide for High-Risk Prostate Cancer After Surgery
Fujian Medical University Union Hospital
Phase NA Not yet recruiting
NCT05700903 2026-03-02
ARCH
University of Colorado, Denver
Phase 4 Completed
NCT05617885 2026-02-27
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT01786265 2026-02-20
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06305598 2026-02-19
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT07158021 2026-02-13
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT05320406 2026-02-12
REVELUTION
Emory University
Phase 2 Active not recruiting
NCT06627530 2026-02-11
COAction
Brazilian Clinical Research Institute
Phase 4 Active not recruiting
NCT03902951 2026-02-05
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04455750 2026-02-05
CASPAR
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT04734730 2026-01-28
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT06397703 2026-01-28
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
NYU Langone Health
Phase 2 Recruiting
NCT02772588 2026-01-27
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05498272 2026-01-23
NePtune
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT04126070 2026-01-22
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06734130 2026-01-21
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03070886 2026-01-14
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
Phase 2/3 Completed
NCT04513717 2026-01-14
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT06059118 2026-01-14
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT01746849 2026-01-07
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT00329043 2025-12-26
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT03007732 2025-12-05
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
Phase 2 Completed
NCT05189457 2025-12-04
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT07159451 2025-12-01
POP-ELA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT02023463 2025-11-25
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT04569747 2025-11-13
ADEPT
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06348264 2025-09-23
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
Peking University First Hospital
Phase 2 Recruiting
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT07179939 2025-09-18
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase 2 Not yet recruiting
NCT06922318 2025-09-17
The COSMYC Trial (COmbined Suppression of MYC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06145308 2025-09-15
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT06512207 2025-09-09
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Jinzhou Medical University
Phase NA Recruiting
NCT05765500 2025-08-11
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT04181203 2025-07-30
CARLHA-2
UNICANCER
Phase 3 Active not recruiting
NCT07027124 2025-06-18
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Not yet recruiting
NCT02903368 2025-06-13
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04194554 2025-06-04
ASCLEPIuS
University of Michigan Rogel Cancer Center
Phase 1/2 Active not recruiting
NCT02278185 2025-05-11
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Phase 2 Completed
NCT00544830 2025-05-07
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03361735 2025-05-02
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02346253 2025-04-03
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Stanford University
Phase NA Active not recruiting
NCT05169112 2025-03-20
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Ottawa Hospital Research Institute
Phase 3 Recruiting
NCT02685397 2024-12-04
PCS IX
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2/3 Active not recruiting
NCT01442246 2024-09-19
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.
UNICANCER
Phase 3 Active not recruiting
NCT03900637 2024-07-31
PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate
Seoul National University Hospital
Phase 2 Active not recruiting